Esophageal Cancer
Pembrolizumab as second-line therapy improved overall survival (OS) in patients with advanced or metastatic esophageal cancer and high PD-L1 expression compared with chemotherapy, according to findings from the phase 3 KEYNOTE-181 study presented at the 2019 Gastrointestinal Cancers Symposium.
Adjuvant treatment with durvalumab, a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial.
Results 1 - 2 of 2